{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:46:53Z","timestamp":1778766413952,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ihj.2023.12.010","type":"journal-article","created":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T16:56:30Z","timestamp":1703868990000},"page":"S117-S120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"S1","title":["Lipoprotein a - Lp(a)"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6001-6069","authenticated-orcid":false,"given":"Tapan","family":"Ghose","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.ihj.2023.12.010_bib1","first-page":"e1082","volume":"139","author":"Grundy","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ihj.2023.12.010_bib2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ihj.2019.03.004","article-title":"Lipoprotein(a): an independent, genetic, and causal factor for cardiovascular disease and acute myocardial infarction","volume":"71","author":"Enas","year":"2019","journal-title":"Indian Heart J"},{"key":"10.1016\/j.ihj.2023.12.010_bib3","series-title":"Quoted in Lipoprotein (A) and Atherosclerosis, Handbook of Lipidology","author":"Dev","year":"2016"},{"key":"10.1016\/j.ihj.2023.12.010_bib4","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/650989","article-title":"Lipoprotein(a) in cardiovascular disease","volume":"2013","author":"Malaguarnera","year":"2013","journal-title":"Biomedical research International"},{"issue":"3","key":"10.1016\/j.ihj.2023.12.010_bib5","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Lipidology Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"Journal of Clinical Lipidology"},{"issue":"22","key":"10.1016\/j.ihj.2023.12.010_bib6","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.ihj.2023.12.010_bib7","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"INTERHEART investigators. Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Par\u00e9","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ihj.2023.12.010_bib8","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2015.08.021","article-title":"Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis","volume":"242","author":"Nave","year":"2015","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.ihj.2023.12.010_bib9","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.10.013","article-title":"Lipoprotein(a), ferritin, and albumin in acute phase reaction predicts severity and mortality of acute ischemic stroke in North Indian Patients","volume":"22","author":"Chakraborty","year":"2013","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.ihj.2023.12.010_bib10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.atherosclerosis.2019.07.025","article-title":"Serum lipoprotein (a) is associated with increased risk of stroke in Chinese adults: a prospective study","volume":"289","author":"Zhang","year":"2019","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.ihj.2023.12.010_bib11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1161\/STROKEAHA.116.014436","article-title":"Lipoprotein(a) levels and recurrent vascular events after first ischemic stroke","volume":"48","author":"Lange","year":"2017","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.ihj.2023.12.010_bib12","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.ihj.2023.12.010_bib13","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.ihj.2023.12.010_bib14","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3390\/biom9120760","article-title":"Lipoprotein(a) as orchestrator of calcific aortic valve stenosis","volume":"9","author":"Schnitzler","year":"2019","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.ihj.2023.12.010_bib15","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ihj.2019.04.007","article-title":"Lipoprotein(a): an underrecognized genetic risk factor for malignant coronary artery disease in young Indians","volume":"71","author":"Enas","year":"2019","journal-title":"Indian Heart J"},{"key":"10.1016\/j.ihj.2023.12.010_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/CE.S174169","article-title":"Lomitapide: a review of its clinical use, efficacy, and tolerability","volume":"14","author":"Alonso","year":"2019","journal-title":"Core Evid"},{"key":"10.1016\/j.ihj.2023.12.010_bib17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.athplu.2021.05.001","article-title":"Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: analysis on cytokines and lipid profile","volume":"43","author":"Lupo","year":"2021","journal-title":"Atherosclerosis Plus"},{"key":"10.1016\/j.ihj.2023.12.010_bib18","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lopoprotein(a), PCSK9 inhibition and cardiovascular risk insights from the fourrier trial","volume":"139","author":"O'Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"44","key":"10.1016\/j.ihj.2023.12.010_bib19","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"ODYSSEY OUTCOMES Investigators. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ihj.2023.12.010_bib20","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2147\/TCRM.S230592","article-title":"Inclisiran for the treatment of cardiovascular disease: a short review on the emerging data and therapeutic potential","volume":"16","author":"Kosmas","year":"2020","journal-title":"Therapeut Clin Risk Manag"},{"issue":"3","key":"10.1016\/j.ihj.2023.12.010_bib21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: first approval [published correction appears in drugs","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ihj.2023.12.010_bib22","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1097\/FJC.0000000000001045","article-title":"The role of antisense therapies targeting lipoprotein(a)","volume":"78","author":"Plakogiannis","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"issue":"12","key":"10.1016\/j.ihj.2023.12.010_bib23","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jacc.2021.01.051","article-title":"Emerging RNA therapeutics to lower blood levels of lp(a): JACC focus seminar 2\/4","volume":"77","author":"Tsimikas","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"1\u20131","key":"10.1016\/j.ihj.2023.12.010_bib24","first-page":"111","article-title":"ESC\/EAS guideline for the management of dyslipidemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"14","author":"Francois","year":"2019","journal-title":"Eur Heart J"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483223004790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0019483223004790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T01:38:20Z","timestamp":1712626700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0019483223004790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":24,"alternative-id":["S0019483223004790"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2023.12.010","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein a - Lp(a)","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2023.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Cardiological Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}